New study aims to replace costly PET scans with MRI and blood tests for Alzheimer's patients

NCT ID NCT07456462

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test whether advanced MRI scans and blood tests can predict how well Alzheimer's patients respond to antibody drugs like lecanemab and donanemab. Researchers aim to create personalized models that show when amyloid plaques have been cleared from the brain, potentially replacing expensive PET scans. Fifty participants with early Alzheimer's will be followed for 18 months to see if these non-invasive methods can guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
monoclonal antibodies (lecanemab or donanemab)
What this could lead to
If successful, this could lead to a safer, cheaper way to monitor Alzheimer's treatment and decide when to stop medication, tailored to each patient.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply to everyone. The models are still being developed and may not accurately predict treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • San Raffaele Neurology Unit

    Milan, Milano, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.